
1. hum gene ther clin dev. 2013 mar;24(1):29-37. doi: 10.1089/humc.2013.006. epub
2013 apr 3.

preclinical safety, toxicology, biodistribution study adenoviral gene
therapy svegfr-2 svegfr-3 combined chemotherapy ovarian cancer.

tuppurainen l(1), sallinen h, kokki e, koponen j, anttila m, pulkkinen k, heikura
t, toivanen p, hämäläinen k, kosma vm, heinonen s, alitalo k, ylä-herttuala s.

author information: 
(1)department molecular medicine, a.i. virtanen institute, university of
eastern finland, kuopio, fin-70211, finland.

abstract antiangiogenic antilymphangiogenic gene therapy soluble
vascular endothelial growth factor receptor-2 (vegfr-2) soluble vegfr-3 in
combination chemotherapy potential new treatment ovarian carcinoma.
we evaluated safety, toxicology, biodistribution intravenous
adsvegfr-2 adsvegfr-3 combined chemotherapy healthy rats (n=90)
before entering clinical setting. study groups were: adlacz adlacz with
chemotherapy control groups, low dose adsvegfr-2 adsvegfr-3, high dose
adsvegfr-2 adsvegfr-3, combination low dose adsvegfr-2 adsvegfr-3 with
chemotherapy, combination high dose adsvegfr-2 advegfr-3 with
chemotherapy, chemotherapy only. follow-up time 4 weeks. safety and
toxicology assessed monitoring clinical status animals 
histological, hematological, clinical chemistry parameters. the
biodistribution studies, quantitative reverse-transcriptase polymerase chain
reaction (qrt-pcr) enzyme-linked immunosorbent assay (elisa) used. low
dose (2×10(10) vp) adsvegfr-2 adsvegfr-3 gene therapy well tolerated,
even gene therapy combined chemotherapy. notably, transient
elevation liver enzymes mild regenerative changes seen liver after
the gene transfer groups received high doses (2×10(11) vp) of
adsvegfr-2 adsvegfr-3 without chemotherapy. life-threatening
adverse effects noticed treatment groups. highest protein 
concentration soluble vegfr-2 (svegfr-2) circulation seen 1 week 
the gene transfer. combination chemotherapy gene therapy seemed to
prolong time detectable transgene protein least 1 week the
circulation. expression adsvegfr-2 adsvegfr-3 transgenes mainly
seen liver spleen detected qrt-pcr. according results, 
adsvegfr-2 adsvegfr-3 gene therapy combined chemotherapy safe can
be brought clinical testing ovarian cancer patients.

doi: 10.1089/humc.2013.006 
pmid: 23692381  [indexed medline]

